Emily Kramer-Golinkoff struggles to breathe easily. Living with advanced cystic fibrosis, she finds everyday tasks like walking and showering draining and difficult.Cystic fibrosis is the most common fatal genetic disease in the United States, affecting around 40,000 people. Yet Kramer-Golinkoff’s case is particularly challenging because her condition stems from a rare mutation. As a result, the treatments that benefit 90% of cystic fibrosis patients are ineffective for her.This situation isn’t unique to cystic fibrosis. Across many genetic diseases, major scientific breakthroughs have uncovered hidden mutations behind severe illnesses and led to life-changing treatments. However, for patients with rare genetic variations, therapeutic options remain limited, forcing them to place their hopes in emerging gene therapies.“We feel pure joy for our friends who have been saved from this sinking ship,” said Kramer-Golinkoff, 40. “But we’re also desperate to join them. It’s incredibly hard to be among the few left behind.”The difficulty isn’t just scientific—market forces are also at play. Drug companies prioritize developing treatments for the most common mutations to ensure larger markets.“You need a large enough patient group in a major market for a company to stay interested,” explained Dr. Kiran Musunuru, a gene-editing specialist at the University of Pennsylvania. This results in what he calls “mutational discrimination.”Charities like Emily’s Entourage, a nonprofit Kramer-Golinkoff helped establish, aim to break these barriers. Their fundraising has fueled early-stage gene therapy research that could benefit patients regardless of their specific mutations.Although widespread availability of these therapies is still years away, “just having these treatments enter clinical trials provides immense hope,” Kramer-Golinkoff said.Kramer-Golinkoff’s journey with cystic fibrosis began when she was diagnosed at six weeks old. The disease causes thick, sticky mucus to build up in the body due to a malfunctioning CFTR protein, leading to infections, blockages, and organ damage.Despite her best efforts, her condition has deteriorated over time. She earned a master’s degree in bioethics, traveled, worked, and built friendships, but eventually developed CF-related diabetes and other complications. The pandemic forced her into isolation with her parents in the Greater Philadelphia area.“CF is truly a monster of a disease,” she said.Meanwhile, many others with cystic fibrosis have experienced remarkable health improvements thanks to CFTR modulator therapies that correct the defective protein. These treatments significantly boost lung function, alleviate respiratory symptoms, and enhance overall quality of life.Unfortunately, these modulators aren’t an option for patients with rare or unknown mutations. Gaps in genetic testing, particularly in underrepresented communities, contribute to these inequities. Research indicates that Black cystic fibrosis patients are more likely than white patients to fall into the group who don’t benefit from available therapies.To address these disparities, scientists are focusing on “mutation-agnostic” gene therapies—treatments designed to work across all mutations. This strategy is gaining traction in diseases affecting both the lungs and the eyes.“There’s a strong push to develop these therapies,” said Dr. Garry Cutting of the Johns Hopkins Cystic Fibrosis Center.Most of the 14 experimental gene therapies for cystic fibrosis aim to deliver healthy CFTR genes directly into patients' cells, correcting the underlying defect regardless of the mutation.One such therapy, partially funded by Emily’s Entourage, began a clinical trial in November at Columbia University. The goal is to assess the treatment’s safety and effectiveness.Despite her worsening condition—living with just 30% lung function, diabetes, and lung hypertension—Kramer-Golinkoff remains hopeful.“You have to make careful choices about how to spend your limited energy,” she said. “But we’re incredibly excited about the promise of gene therapies. They can’t come soon enough.”